Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Gross Margin (2016 - 2025)

Adma Biologics (ADMA) has disclosed Gross Margin for 13 consecutive years, with 63.82% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 994.0% year-over-year to 63.82%, compared with a TTM value of 57.39% through Dec 2025, up 590.0%, and an annual FY2025 reading of 57.39%, up 590.0% over the prior year.
  • Gross Margin was 63.82% for Q4 2025 at Adma Biologics, up from 56.34% in the prior quarter.
  • Across five years, Gross Margin topped out at 159.53% in Q4 2022 and bottomed at 10.73% in Q1 2021.
  • Average Gross Margin over 5 years is 37.63%, with a median of 35.54% recorded in 2023.
  • The sharpest move saw Gross Margin skyrocketed 32695bps in 2021, then tumbled -11747bps in 2023.
  • Year by year, Gross Margin stood at 6.38% in 2021, then skyrocketed by 2399bps to 159.53% in 2022, then tumbled by -74bps to 42.06% in 2023, then rose by 28bps to 53.88% in 2024, then rose by 18bps to 63.82% in 2025.
  • Business Quant data shows Gross Margin for ADMA at 63.82% in Q4 2025, 56.34% in Q3 2025, and 55.11% in Q2 2025.